IP Cases — 2023
1,252 decisions across all jurisdictions
Page 33 of 42 · 1,252 total
Vaibhav Chaurasia v.Union Of India
The Delhi High Court disposed of a writ petition filed by Vaibhav Chaurasia seeking directions against the Union of India regarding the status of Trade Mark No. 2650542. The petitioner had applied for the substitution of his name as the proprietor following an assignment from M/s Delicious Food Products Pvt Ltd. Recognizing the limited nature of the grievance, the Court directed the Registrar of Trademarks to process and decide the application within a period of six weeks.
Immunovative Therapies Ltd. v.The Controller Of Patents
Immunovative Therapies Ltd. appealed a rejection order dated December 4, 2018, concerning its patent application for 'TH1 VACCINATION PRIMING FOR ACTIVE IMMUNOTHERAPY'. The appellant argued that the rejection based on Section 3(d) and (i) was incorrect, as the invention relates to therapeutic vaccine methods using allogeneic CD3/CD28 cross-linked Thl memory cells.
Esteve Pharmaceuticals S.A. v.Controller Of Patents And Designs
Esteve Pharmaceuticals S.A. appealed a rejection order issued by the Controller of Patents and Designs regarding its Indian Patent Application No. 1435/DELNP/2012. The application, which relates to a co-crystal formulation of Tramadol and Celecoxib, was rejected for lacking novelty and inventive step under Section 3(d) and (e).
A Dot Limited v.Registrar Of Trade Marks
The Delhi High Court allowed the appeal filed by A Dot Limited against the Registrar of Trade Marks' refusal to register the trademark 'WHAT DO YOU SEE?'. The court held that a combination of dictionary words forming a tagline can function as a source identifier, provided it does not describe the features or quality of the goods/services. Recognizing the mark's use as an expressive prompt rather than a descriptive feature, the High Court set aside the refusal and directed the Registry to process the application, while ensuring the rights are limited strictly to the phrase 'WHAT DO YOU SEE?'
Beiersdorf Ag v.Rsh Global Private Limited & Anr.
This order addressed an application by Beiersdorf Ag alleging that Rsh Global Private Limited was disobeying previous court injunctions regarding the use of deceptively similar cosmetic packaging. The plaintiff pointed out that the defendant's product remained available on various e-commerce websites despite the existing restraint orders. The defendants countered, stating they were actively contacting these third-party sites to have the products removed. Given the complexity of enforcement across multiple online platforms, the court granted a short adjournment to allow further submissions on this critical issue.
Red Bull Ag v.Vandana Chetankumar Maraviya Trading As Vandana Beverages & Ors.
In a trademark infringement suit, Red Bull Ag sought an interim injunction against Vandana Beverages for allegedly using similar marks and trade dresses. The Delhi High Court granted a temporary restraint order, compelling Defendants No. 1 and 3 to immediately cease the use of the disputed marks and remove online advertisements. Crucially, the court allowed them to continue selling existing stock already manufactured and distributed, balancing protection of IP rights with commercial realities.
Akzo Nobel Coatings International B.V. v.Ambience Limited And Anr
The Delhi High Court addressed a trademark dispute concerning the identical mark 'AMBIANCE'. After considering arguments regarding co-existence under Section 12 of the Trade Marks Act, 1999, the court ruled in favor of Akzo Nobel Coatings International B.V. The judgment directs the Registry not to consider Ambience Limited's existing application for 'AMBIANCE' in Class 02 when evaluating the petitioner's applications, thereby allowing both parties to use the mark concurrently on the register.
Bristol-Myers Squibb Holdings Ireland Unlimited Company v.Indoco Remedies Limited
The dispute between Bristol-Myers Squibb Holdings Ireland and Indoco Remedies Limited regarding the validity and infringement of patent IN 247381 for Apixaban was amicably resolved through mediation. The defendant acknowledged the patent's validity until its expiry date (September 17, 2022) and confirmed discontinuing all related activities.
Bristol-Myers Squibb Holdings Ireland Unlimited Company v.Metrochem Api Private Limited
The dispute between Bristol-Myers Squibb Holdings Ireland and Metrochem Api Private Limited regarding patent infringement of Apixaban was amicably resolved through court-mediated conciliation. The parties executed a Settlement Agreement, leading to the suit being decreed in terms of that agreement.
Sanjay Mehra v.Sharad Mehra & Ors.
This suit was filed by Sanjay Mehra seeking permanent injunction against Sharad Mehra & Ors. for alleged infringement and passing off related to the 'SUPERON' trademark and associated intellectual property rights. The core dispute revolved around the division of business assets, including IP, between two groups (SM Group and SDM Group) as per a Memorandum of Family Settlement (MOFS). Although the Plaintiff argued jurisdiction over the matter, the Court ultimately found that arbitration was the intended forum for resolving disputes arising from the MOFS and Sale Deed.
Ace Technologies Corp & Ors. v.Communication Components Antenna Inc.
This appeal challenged an interim injunction granted by the Delhi High Court, which restrained Ace Technologies Corp from manufacturing and selling antennae due to alleged infringement of Patent IN240893. The respondent claimed its patent covered a novel asymmetrical beam pattern for fixed antennas used in cellular networks. While the court found no grounds to interfere with the core interim relief, it modified the financial compliance terms, allowing the respondents to deposit a bank guarantee instead of cash.
Trex India Pvt. Ltd. v.Cde Asia Limited
The dispute originated from a suit for permanent injunction filed by Cde Asia Limited against Trex India Pvt. Ltd. regarding alleged infringement of its Patent No. 3072491 and Design No. 2626292 concerning the product 'FM 120 CONEXUS'. The present appeal challenged the Single Judge's order, but the High Court dismissed the appeal on a preliminary objection regarding its maintainability under the Commercial Courts Act.
S. N. Biri Factory Private Limited v.Mukesh Chand Khandelwal & Anr.
The Delhi High Court addressed a dispute concerning artistic works used in matchstick branding, where the Petitioner alleged that Respondent No. 1's new copyright was deceptively similar to their existing registered designs and trademarks. Despite the Deputy Registrar of Copyrights initially rejecting the objection, the Court found prima facie evidence suggesting imitation of unique features and misappropriation of phrases like 'शहे नशाह मािचस NO. 99'. Consequently, the High Court granted a stay on the effect of the impugned copyright registration while the matter proceeds.
Leeford Healthcare Limited v.Vobb Healthcare & Ors.
The Delhi High Court granted an ad-interim injunction in favor of Leeford Healthcare Limited against Vobb Healthcare & Ors. The court found a prima facie case of trademark infringement and passing off, specifically concerning the medicinal cream brand 'DERMIFORD.' Given that the goods are pharmaceutical and the defendants had recently entered the market, the court held that Leeford would suffer grave injury without immediate protection. This order temporarily halts the defendants from using deceptively similar marks like 'NEO DERMIFORD' until further orders.
L'Oreal S.A. v.Tarun Sankhla trading as M/s LEORA COSMETICS
L'Oreal S.A. filed a suit seeking permanent injunction against Tarun Sankhla (trading as M/s LEORA COSMETICS) for infringing its trademarks, passing off, and diluting its brand reputation in the cosmetics market. The court found that the defendant was using deceptively similar marks and tradenames, leading to the decreeing of the plaintiff's suit.
Puma Se v.Naveen Sikka And Anr
The Delhi High Court allowed Puma Se's petition to cancel a specific trademark registered by Naveen Sikka and Anr. The judgment followed a settlement agreement reached between the parties, which was found to be lawful. Consequently, the court ordered the removal of the impugned mark from the Register of Trade Marks in Class 9.
M/S.Mahavir Pvc Cables Factory v.M/S.Indo Mahaveer Kable
The Orissa High Court granted a temporary injunction in favor of M/S. Mahavir PVC Cables Factory against M/S. Indo Mahaveer Kable. The court found that the Respondent's use of 'INDO MAHAVEER KABLE' was phonetically and visually deceptive to the Plaintiff’s reputed trade mark, 'MAHAVIR'. Crucially, the court also considered the public interest, noting that the Defendant was using sub-standard materials in their products, thereby protecting consumers from potential harm. This ruling reinforces the importance of preventing market confusion and ensuring consumer safety when dealing with trademark disputes.
Cellresearch Corporation Pte Ltd v.Controller Of Patents And Designs
The appeal challenges an order rejecting Cellresearch Corporation's divisional patent application (No. 10875/DELNP/2013) based on lack of distinct invention from its parent application (No. 1492/DELNP/2007). The appellant argues that the rejection is invalid because the objections raised in the parent application had already been complied with.
Janssen Pharmaceuticals Inc And Others v.Clevus Lifesciences and others
The plaintiffs, exclusive licensees of the patent holder for Indian Patent No. 232231, filed a suit alleging infringement by defendant No. 1 and others who were manufacturing and offering Canagliflozin tablets under brand names like Adkana. The court found a prima facie case in favor of the plaintiffs.
M/s.Fair Beat Herbals Cosmetics Private Ltd. v.The Registrar of Trademarks
The Madras High Court addressed writ petitions challenging trademark registration proceedings involving 'Fair Beat'. The court noted that objections had been raised against the application, and an inquiry was pending before the Trademark Registry. Consequently, the High Court directed the Registrar of Trademarks to conduct a thorough enquiry, ensuring all parties are given an opportunity to participate, and to pass final orders on the merits as quickly as possible.
Boehringer Ingelheim Pharma Gmbh & Co. v.Vee Excel Drugs And Pharmaceuticals Private Ltd.
Boehringer Ingelheim Pharma filed multiple suits seeking permanent injunction against generic drug manufacturers, including Vee Excel Drugs, alleging infringement of Indian Patent No. IN 243301 related to Linagliptin compounds. The Delhi High Court examined the applications for interim injunction across all connected matters. The court found that the patent was vulnerable to revocation due to prior claiming and noted attempts at evergreening by the patentees. Consequently, the plaintiffs failed to establish a prima facie case, leading to the dismissal of all interim injunction applications.
Boehringer Ingelheim Pharma Gmbh & Co. v.Vee Excel Drugs And Pharmaceuticals Private Ltd.
This judgment addresses multiple suits filed by Boehringer Ingelheim Pharma against various Indian pharmaceutical companies, seeking permanent injunctions against infringing Patent No. IN 243301 related to Linagliptin tablets. The Delhi High Court examined the prima facie case and found that the patent was vulnerable to revocation due to prior claiming and attempts at evergreening by the plaintiffs. Consequently, the court dismissed all applications for interim injunction, allowing defendants to manufacture and sell products containing Linagliptin as the active pharmaceutical ingredient.
Intex Technologies (India) Ltd v.Telefonaktiebolaget L M Ericsson (Pub)
This Delhi High Court judgment addressed cross-appeals concerning the validity and infringement of Standard Essential Patents (SEPs) related to telecom technology. The court affirmed that Ericsson's patents were prima facie essential and infringed, finding Intex to be an unwilling licensee. Despite arguments regarding SEPs being unknown in Indian law, the court upheld the necessity of FRAND compliance to ensure parity with global implementers.
Ifp Energies Nouvelles v.The Assistant Controller of Patents and Designs, Government of India
Ifp Energies Nouvelles appealed the rejection of its patent application (No. 1373/CHE/2015) by the Controller of Patents and Designs, Chennai. The appellant argued that the rejection order was non-speaking and failed to consider their submissions or prior acceptance in the USA. The High Court agreed, finding that the material contentions were ignored.
Boehringer Ingelheim Pharma Gmbh And Co. Kg & Anr. v.Alkem Laboratories Ltd & Anr., Vee Excel Drugs and Pharmaceuticals Private Ltd. & Ors., Micro Labs Limited, Natco Pharma Limited & Anr., Mankind Pharma Limited
This judgment addresses multiple suits filed by Boehringer Ingelheim Pharma against various Indian pharmaceutical companies seeking permanent injunctions for infringing Patent No. IN 243301, which covers Linagliptin compounds. The Delhi High Court found that the plaintiffs failed to establish a prima facie case for granting interim relief. Furthermore, the court expressed concern regarding the patent's vulnerability due to prior claiming and alleged attempts at 'evergreening.' Consequently, all applications for injunction were dismissed, allowing defendants to continue manufacturing and selling products containing Linagliptin.
Boehringer Ingelheim Pharma Gmbh And Co. Kg & Anr. v.Vee Excel Drugs and Pharmaceuticals Private Ltd. & Ors., Alkem Laboratories Ltd & Anr., Micro Labs Limited, Natco Pharma Limited & Anr., Mankind Pharma Limited
Boehringer Ingelheim Pharma sought permanent injunctions against various Indian pharmaceutical companies, alleging infringement of Patent No. IN 243301 related to Linagliptin tablets. The Delhi High Court examined the applications for interim injunction across multiple connected suits. The court found that the plaintiffs failed to establish a prima facie case, noting concerns about potential patent vulnerability due to prior claiming and attempts at evergreening. Consequently, all interim injunction applications were dismissed, allowing defendants to continue manufacturing and selling the products.
Boehringer Ingelheim Pharma Gmbh And Co. Kg & Anr. v.Mankind Pharma Limited
Boehringer Ingelheim Pharma filed multiple suits seeking permanent injunction against Indian pharmaceutical companies for allegedly infringing Patent No. IN 243301, which covers Linagliptin compounds. The Delhi High Court examined the applications for interim injunction across all connected matters. The court found that the suit patent was vulnerable to revocation due to prior claiming and noted attempts by the plaintiffs towards 'evergreening.' Consequently, the court dismissed all applications for interim injunction, allowing defendants to manufacture and sell products containing Linagliptin.
Telefonaktiebolaget Lm Ericsson (Pub) v.Intex Technologies (India) Limited
This Delhi High Court judgment addressed a complex dispute involving Standard Essential Patents (SEPs) between Ericsson and Intex. The court examined whether the patents were essential, if Intex was infringing them, and if Intex had acted as an unwilling licensee despite Ericsson's FRAND commitments. Ultimately, the court found that the patents were prima facie valid and infringed, compelling Intex to pay the full royalty amount.
Boehringer Ingelheim Pharma Gmbh And Co. Kg & Anr. v.Vee Excel Drugs and Pharmaceuticals Private Ltd. & Ors., Alkem Laboratories Ltd & Anr., Micro Labs Limited, Natco Pharma Limited & Anr., Mankind Pharma Limited
This judgment addresses multiple suits filed by Boehringer Ingelheim Pharma seeking permanent injunction against various Indian pharmaceutical companies for infringing Patent No. IN 243301, which covers Linagliptin compounds. The court examined the applications for interim injunction and found that the plaintiffs failed to establish a prima facie case. Furthermore, the judge expressed concerns regarding the patent's vulnerability due to prior claiming and alleged attempts at evergreening by the patentees. Consequently, all interim injunction applications were dismissed, allowing the defendants to continue manufacturing and selling products containing Linagliptin.
Diamond Star Global Sdn. Bhd. v.Joint Controller Of Patents And Designs
The appellant sought a patent for 'Hygiene Wash,' a skin care preparation using wood vinegar derived from the Rhizophora apiculata tree. The Controller rejected the application, but the High Court found that the invention possessed an inventive step by identifying guaiacol-free wood vinegar and determining the optimal concentration (18-22%) to selectively target harmful bacteria while preserving beneficial lactic acid bacteria.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.